PROTOS 2C卷烟机通过压缩空气向胶水桶内加压以保证连续不断向喷胶嘴供胶,但容易出现胶水桶内表层胶水产生胶皮和凝结成块,堵塞胶水管路及喷嘴的情况,针对这个问题,我们在继续使用原有压缩空气系统的情况下,在桶盖上原有安全阀位置处安...PROTOS 2C卷烟机通过压缩空气向胶水桶内加压以保证连续不断向喷胶嘴供胶,但容易出现胶水桶内表层胶水产生胶皮和凝结成块,堵塞胶水管路及喷嘴的情况,针对这个问题,我们在继续使用原有压缩空气系统的情况下,在桶盖上原有安全阀位置处安装快插气管接头,接入或门型梭阀,使得压缩空气不向外界排出,不带走胶水水分,问题得到解决。目前已应用于卷包一车间10台PROTOS 2C卷接机组,应用效果良好。The PROTOS 2C cigarette machine pressurizes the glue bucket with compressed air to ensure continuous supply of glue to the spray nozzle. However, it is prone to the occurrence of glue on the surface of the glue bucket forming rubber skin and clumping, blocking the glue pipeline and nozzle. In response to this problem, we have installed a quick insertion air pipe joint at the original safety valve position on the bucket cover while continuing to use the original compressed air system, and connected it to a door type shuttle valve to prevent compressed air from being discharged to the outside and not taking away glue moisture, thus solving the problem. At present, it has been applied to 10 PROTOS 2C winding and splicing units in the first packaging workshop, and the application effect is good.展开更多
BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in ...BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,expression of BRAF mutation,and additional mutations were registered.The BRAF V600E mutation was found in 297 AM(57%),63 UA(77.7%),3 AC(23%),1 MA(50%),and 5 PA(83.3%).Follicular type predominated with a total of 116 cases(40%),followed by plexiform type with 63 cases(22.1%).Furthermore,both types presented additional mutations,in which alterations in JAK3 P132T,SMARCB1,PIK3CA,CTNNB1,SMO,and BRAF G606E genes were found.Four case reports were found with targeted therapy to BRAF V600E.CONCLUSION The identification of BRAF V600E and additional mutations as an aid in targeted therapies has been a breakthrough in alternative treatments of ameloblastomas where surgical treatments are contraindicated.展开更多
文摘PROTOS 2C卷烟机通过压缩空气向胶水桶内加压以保证连续不断向喷胶嘴供胶,但容易出现胶水桶内表层胶水产生胶皮和凝结成块,堵塞胶水管路及喷嘴的情况,针对这个问题,我们在继续使用原有压缩空气系统的情况下,在桶盖上原有安全阀位置处安装快插气管接头,接入或门型梭阀,使得压缩空气不向外界排出,不带走胶水水分,问题得到解决。目前已应用于卷包一车间10台PROTOS 2C卷接机组,应用效果良好。The PROTOS 2C cigarette machine pressurizes the glue bucket with compressed air to ensure continuous supply of glue to the spray nozzle. However, it is prone to the occurrence of glue on the surface of the glue bucket forming rubber skin and clumping, blocking the glue pipeline and nozzle. In response to this problem, we have installed a quick insertion air pipe joint at the original safety valve position on the bucket cover while continuing to use the original compressed air system, and connected it to a door type shuttle valve to prevent compressed air from being discharged to the outside and not taking away glue moisture, thus solving the problem. At present, it has been applied to 10 PROTOS 2C winding and splicing units in the first packaging workshop, and the application effect is good.
文摘BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,expression of BRAF mutation,and additional mutations were registered.The BRAF V600E mutation was found in 297 AM(57%),63 UA(77.7%),3 AC(23%),1 MA(50%),and 5 PA(83.3%).Follicular type predominated with a total of 116 cases(40%),followed by plexiform type with 63 cases(22.1%).Furthermore,both types presented additional mutations,in which alterations in JAK3 P132T,SMARCB1,PIK3CA,CTNNB1,SMO,and BRAF G606E genes were found.Four case reports were found with targeted therapy to BRAF V600E.CONCLUSION The identification of BRAF V600E and additional mutations as an aid in targeted therapies has been a breakthrough in alternative treatments of ameloblastomas where surgical treatments are contraindicated.
